Last reviewed · How we verify
Pneumococcal vaccine GSK2189242A
At a glance
| Generic name | Pneumococcal vaccine GSK2189242A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination (PHASE2)
- Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children (PHASE2)
- Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults (PHASE2)
- Evaluation of Pneumococcal Vaccine Formulations in Young Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal vaccine GSK2189242A CI brief — competitive landscape report
- Pneumococcal vaccine GSK2189242A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI